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Summary
Low molecular weight (LMW) heparin preparations have
unknown distributions of ATIII-binding material, so mean
molecular weights as such might bear little information on their
anti-factor Xa and anti-thrombin activities, and on the neutraliza-
tion of these activities by platelet factor 4 (PF4). These properties
were investigated in pure systems with proteins of human origin.
Pseudo-first order rate constants of inactivation of factor Xa and
thrombin by antithrombin III were determined as function of
heparin concentration, in the presence of 4.0 mM CaCl2. Despite
alarge variation in the mean molecular weights, the ratios of the
anti-factor Xa over the anti-thrombin activities were essentially
the same for the 4th International Standard for heparin (0.46), the
1st International Standard for LMW heparin (0.32), CY2t6 (0.42)
and enoxaparin (0.50). The ultra LMW heparin CY222 had only a
2-times higher ratio (0.98). Analysis of CY2l6 subfractions,
obtained by gel filtration, showed that the heparin molecules of
the upper region of the molecular weight distribution are respon-
sible for the anti-thrombin, but also to a large extent for the anti-
factor Xa activities. The results indicate that depolymerization of
unfractionated heparin does not result in an increased anti-
factor Xalanti-thrombin ratio, because in the presence of Ca2+-
ions the rate constants of inactivation of factor Xa are lowered as
compared to those of native heparin. PF4-dependent neutraliza-
tion of anti-factor Xa and anti-thrombin activities of fixed con-
centrations of the LMW heparins was studied by measuring rate
constants as function of PF4 concentration. All anti-thrombin and
50"/" of the anti-factor Xa activities were readily neutralized.
Excess PF4 was required to neutralize another 35-50% of the
anti-factor Xa activities. At PF4 levels obtained at maximal
release ofthe content ofplatelet o-granules, all anti-thrombin and
most (>85%) of the anti-factor Xa activities can be neutralized.
lntroduction
Unfractionated (UF) and low molecular weight (LMW) hepa-
rins inhibit blood coagulation by potentiating the anti-protease
activity of antithrombin III (ATIII) (1). Studies on the structure-
function relationship of heparin demonstrated that its anti-
factor Xa activity depends on the presence of the specific ATIII-
binding pentasaccharide domain (see Ref.2 for a review). The
Abbreviations: ATIII, antithrombin III; LMW, low molecular weight;
UE, unfractionated; MMW, medium molecular weight; PF4, platelet
factor 4; HSA, human serum albumin; 52238, D-phenylalanyl-L
pipecolyl-Larginine-p-nitroanilide dihydrochloride; 52337, benzoyl-l-
isoleucyl-Lglutamyl-(y-piperidyl)-L-glycyl-L-arginine-p-nitroanilide hy-
drochloride.
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sole binding of heparin to ATIII, however, is not sufficient for
catalysis of thrombin inactivation; this process also depends on
the simultaneous binding of thrombin (3, 4). The smallest heparin
fragment with a noticeable anti-thrombin activity is an
octadecasaccharide (5 -7). Studies, utilizing heparin fractions with
high affinity for ATIII obtained by gel filtration and affinity
chromatography on matrix-bound ATIII, have indicated that as
the molecular weights of heparin fractions decrease from 10,000
to 2,000 the anti-thrombin activities vanish, while the anti-
factor Xa activities diminish much less rapidly.
LMW heparin preparations, as obtained by depolymeization
of native heparin, largely consist of molecules with a length of 18
saccharides and less. The lesser ability of these short heparin
chains to enhance thrombin inhibition was thought to explain the
decreased ability of LMW heparin preparations to prolong the
clotting time of global coagulation tests like the aPTT (8, 9).
LMW heparins, now clinically used or intended to be used,
encompass heparin chains in a vast range of molecular weights
(10). In addition to information about the molecular weight
distribution of a particular LMW heparin preparation, it is of
paramount importance to know the distribution of the heparin
chains with affinity for AIIII. This is especially important,
because the LMW heparins available at present are prepared
using a variety of fragmentation methods, which is an important
source for an increase of the inhomogeneity present in UF
heparin (10). For instance, certain depolymerization methods
(especially the nitrous acid hydrolysis) will also result in cleavage
of AIIII-binding sites, which ultimately leads to non-random
distribution of ATIII-high affinity saccharides throughout the
molecular weight distribution profiles of LMW heparins.
Surprisingly, in spite of an extensive research for biological
differences between different LMW heparin preparations, the
distribution of the ATIII-binding oligosaccharides has not been
evaluated. Moreover, anti-protease specific activities of (LMW)
heparin preparations are still determined under rather unphy-
siological conditions: bovine factor Xa or thrombin in a citrated
plasma milieu. At present it has to be realized that the anti-
factor Xa and anti-thrombin activities of heparin are influenced
by free Caz*-ions. The extent to which the kinetics of inhibition of
the proteases are affected by Ca2+ depends on the nature
(factor Xa or thrombin) and origin (bovine or human) of the
protease, and on structural features of the heparin species (chain
length) (11-13).
Differences between LMW heparin preparations, regarding
their molecular weight profiles and the distribution patterns of
their ATIII-high affinity saccharides, might have consequences
for their overall anticoagulant activities, and may influence their
overall sensitivities towards neutralization by heparin-binding
proteins, like platelet factor 4 (PF4). From the work of Lane et al.
(3) it is known that the anti-thrombin and antifactor Xa activities
of heparin molecules with 18 or more monosaccharide units can
be completely neutralized by PF4. However, as the heparin chain
lengths decrease from 18 to 8 saccharides, increasing amounts of
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Table 1 The mean molecuiar weights, and molecular weight distributions of the UF and LMW heparins used in the study
Heparin type Mean M, M, distribution
<2,500
(%)
>7,500
(%)
M, <95o/o 95o/o <M,
UF standard heparinl
LMW standard heparinl
cY2t62
CY216 MMW fraction2
CY216 LMW fractionz
CY21.6 ultra LMW fraction2
Enoxaparin (PK10169)1
cY2222
12,500
6,400
5,100
7,900
4,400
3,100
3,800
3.800
0.5
4
5
0.5
0 .5
24
74
4,4
2,300
6,100
3,300
1,800
2,700
9,400
11,,200
5,500
4,500
9,000
86
24
9
64
0
0
ZJ
2
'See Ref. 10.
2weight average, and distribution provided by Sanofi Recherche.
anti-factor Xa activity iesist neutralization. The platelet protein
PF4, stored in the o,-granules, consists of 4 identical subunits, each
containing a heparin binding site (14). A strong non-specific
electrostatic interaction has been reported between PF4 and
heparin molecules with a chain length of 16 saccharides and more(  l5 )
Mean molecular weights as such might actually have no
predictive value for the anti-thrombin and anti-factor Xa specific
activities of LMW heparins, and their neutralization by heparin-
binding proteins like PF4. This provoked us to initiate a reinvesti-
gation of these properties in well-defined buffer systems, utilizing
LMW heparin preparations which are at present intended for
clinical use and standardization.
Materials and Methods
Proteins
Human PF4 was purified by affinity chromatography on heparin-
Sepharose (16). Briefly, outdated platelet concentrates were pooled, and
the platelets were lysed by the addition of Tiiton X100 to a final
concentration of 1%. The suspension was heated at 56' C for 45 min and
centrifuged at 10,000 x g for 30 min at 4' C Solid ammonium sulfate was
added to the continuously stirred supernatant, to a final concentration of
40To. After centrifugation, supernatant was collected and extensively
dialysed against 50 nM Tiis-HCl (pH 7.5) containing 0.50 M NaCl. The
material was applied to a heparin-Sepharose column (Pharmacia,
Uppsala, Sweden) equilibrated in the same buffer. A linear salt gradient,
from 0.50 to 2.0 M NaCl in 50 mM Tiis-HCl (pH 7.5), was applied and
PF4, assessedby its anti-heparin activity, eluted at about 1.5 M NaCl. The
fractions with the highest PF4 activity were pooled, extensively dialysed
against 50 mM Tiis-HCl (pH 8.0) containing 0.40 M NaCl, and stored at
-70" C The preparation was neither contaminated with heparin nor with
ATIII. The molar concentration was assessed utilizing Erx : 2.9 at a
wavelength of 280 nm (17), and a molecular weight of 3I,200 for the PF4
tetramer.
Human factor Xa and human AIIII were prepared as reported
previously (18). Thrombin was isolated, by chromatography of prothrom-
binase-activated human prothrombin (19) on sulfopropyl-sephadex
(Pharmacia, Uppsala, Sweden) atpH7.4 (20). The molar concentrations
of the factor Xa and thrombin preparations were determined by active site
titration with p-nitrophenyl p'-guanidinobenzoate hydrochloride (21, 22\.
The molar concentration of ATIII was determined by titration with
known amounts of factor Xa. The factor Xa, thrombin and ATIII
preparations were stored in 50 mM Tiis-HCl (pH 7.9) containing 175 mM
NaCl, at -70" C.
Heparins
The 4th International Standard for heparin (UF standard heparin) and
the 1st Intemational Standard for LMW heparin (LMW standard heparin)
+JO
were a kind gift of Dr T W. Barrowcliffe from the National Institute for
Biological Standards and Control (London, United Kingdom). The LMW
heparin preparations CY2L6 (batch P 795 XH) and CY222 (batch
P 227 W}{) were from Sanofi Recherche (Paris, France), and enoxaparin
(PK10169) was obtained from Rhdne-Poulenc (Gennevilliers, France). At
the laboratory of Sanofi Recherche, CY216 was subjected to molecular
weight fractionation by gel filtration, and the molecular weight distribu-
tion patterns of the obtained fractions were established by (HPLC) gel
permeation chromatography (23). Concentrations of ATIII-binding mate-
rial present in the heparin preparations were determined by stoichiometric
titration of ATIII, as monitored by intrinsic fluorescence enhancement
(18). The available molecular weight data of all heparin preparations used
are given in Thble 1
Inactivation of Factor Xa and Thrombin
The heparin-catalyzed inactivations of factor Xa and thrombin by
ATIII were studied under pseudo-first order conditions. Either of the
enzymes was added to a mixture of ATIII and heparin in 50 mM Tiis-HCl
(pH 7.9) containing 175 mM NaCl, 4.0 mM CaCl2 and 0.5 mg HSA,/ml at
37" C. The initial concentrations were 30 nM factor Xa or thrombin and
400 nM ATIII. The heparin concentrations were variable. After 2 min
(factor Xa) or 30 s (thrombin) residual enzyme concentrations were
determined by transferring 20 pl samples to cuvettes containing 0.48 ml of
50 mM Tiis-HCl (pH 7.9), 175 mM NaCl, 20 mM EDTA, 0.5 mg HSA/
ml and 0.22 mM of the appropdate chromogenic substrate (factor Xa:
52337; thrombin: 52238)
The rates of absorbance increase were measured on a thermostated
(37" C) dual wavelength spectrophotometer at 405 nm (reference
wavelength: 500 nm). From the residual factor Xa and thrombin concen-
trations the pseudo-first order rate constants were determined. The
inactivation reactions were shown to fqllow pseudo-first order kinetics up
to at least a 90% inhibition of the initial enzymatic activities. Under the
conditions used, i.e. ATIII concentrations in excess over the heparin
concentrations, and larger than the dissociation constant of the interaction
between heparin and ATIII, essentially all heparin molecules containing
the ATIII-binding region, are complexed with ATIII (12) Therefore, the
pseudo-first order rate constants increase linearly with increasing heparin
concentrations. The heparin-dependent increase of the rate constants, the
anti-factor Xa and anti-thrombin specific catalytic activities, were esti-
mated by linear regression analysis.
Neutralization of heparin activity by PF4. The heparin-catalyzed
ATlll-dependent inactivation of factor Xa or thrombin was studied in the
presence of variable PF4 concentrations. Pseudo-first order rate constants
in the presence of PF4 (k"6") were determined as outlined above From
these values we calculated the extents of neutralization (%) of the anti-
protease activities as follows:
NEUTRALIZATTON = (k - k"bJ/(k- k") x 100%
where k is the pseudo-first order rate constant obtained in the absence of
PF4, and fto is the pseudo-first order rate constant obtained in the absence
of heoarin.
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Fig. 1 Rate constants of factor Xa and thrombin inactiva-
tion as function of the concentration of UF standard
heparin. 30 nM factor Xa (panel A) or thrombin (panel B)
was added to ATIII (400 nM) and heparin, either in the
presence of 4.0 mM CaCl2 (O) or in absence of CaCl2 (A).
Rate constants were determined as outlined in ,,Materials
and Methods". Solid lines were obtained bv linear resres-
sion analysis of the data
Results
UF and LMW Heparin Catalyzed Inactivation of Factor Xa
and Thrombin by ATIII
The pseudo-first order rate constants of inhibition of factor Xa
and thrombin as function of UF standard heparin concentrations
are^shown in Fig. 1. In addition. Fig. 1 also iltustrates the effect of
Ca'*-ions on the heparin-dependent inhibition of thrombin and
factor Xa. Linear regression analysis of the data obtained in the
presence of 4 mM CaC12 gave an anti-factor Xa specific catalytic
activity of 9.8 + 0.4 (SE) min-1 (pg UF heparin/ml)-1 and an
anti-thrombin specific catalytic activity of 2I.2 + 1.8 (SE) min 1
(pg UF heparin/ml)-1. The anti-factor Xa and anti-thrombin
specific activities in the absence of CaCl2 were 4.1 + 0.2 (SE) and
44.6 + 3.8 (SE) min-1 (pg UF heparin/ml)-1, respectively. When
the same determinations were performed at a higher ATIII
concentration (1 pM), the very same values were obtained,
indicating that 0.40 pM ATIII was sufficiently high as to saturate
all the ATIII-binding sites of heparin present (data not shown).
Because of the stimulating effect of Ca2+-ions on the UF heparin-
catalyzed inhibition of factor Xa and its negative effect on the UF
heparin-catalyzed inhibition of thrombin, all further experiments
were performed in the presence of 4 mM CaC12,
The anti-factor Xa and anti-thrombin specific catalytic
activities of a selection of LMW heparin preparations were
determined in the same way, and are depicted in Table 2. The
data show that, concomitant with the decrease of mean molecular
weights, both the anti-thrombin and anti-factor Xa catalytic
activities decrease. Hence, except for CY222, the heparins tested
have rather invariable anti-factor Xalanti-thrombin specific activ_
ity ratios. They were found to vary between 0.3 and 0.5. The ultra
LMW heparin CY222 which, on a weight basis, consists for almost
a quarter of saccharides with M, <2,500 (Table 1), has the lowest
specific catalytic activities, and deviates from the other heoarin
preparations, in that it has a significantly higher anti-fa.to, Xu
over anti-thrombin ratio of 1.
Thus, although the different LMW heparin preparations
include significant amounts of molecules consisting of 1g sac-
charide units and less (M, <5,400), the preparations show a
striking similarity with respect to their anti-factor Xa over anti-
thrombin "activity ratios.
Molecular Weight Fractionation of Cy2I6
The fact that the anti-factor Xa over anti-thrombin activity
ratios do not increase with decreasing molecular weights, as
demonstrated in this study (Table 2), was unexpected. Besides a
diminishing effect of Ca2+-ions on the inhibiiion of factor Xa
when heparins are used with decreasing molecular weights (11,
12), the anti-factor Xa specific activities will also be influenced by
the actual distribution of saccharides with high affinity for ATIII.
We therefore investigated the distribution of the anti-factor Xa
and anti-thrombin activities, and of the ATIII-high affinity
heparin species, of one of the LMW heparin preparations
(CY2l6), over its range of molecular weights. To this end
fractions obtained by gel filtration were studied. The mean
molecular weights and molecular weight distributions of the
obtained medium molecular weight (MMW), LMW, and ultra
LMW fractions are given in Thble 1. The anti-factor Xa and anti-
thrombin catalytic activities as well as the ATIII-bindins
capacities of the three fractions, and of Cy2l6 are siven in
Table 3.
It is seen that, on a weight basis, the ATIII-binding capacities
of the fractions decrease with decreasing mean molecular weishts.
1 0 0
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Flg.2 Neutralization of UF and LMW standard heparin by pF4 pseudo-
first order rate constants of inactivation of 30 nM factor Xa (O) or 30 nM
thrombin (n) by a00 nM ATIII were determined in the presence of
100 ng/ml UF standard heparin (panel A) or 320 nglml LMW standard
heparin (panel B), and variable concentrations of PF4 Neutralization of
the anti-protease activities was assessed as described in ,,Materials and
Methods". Solid lines are linear approximations of the data
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Table 2 Anti-factor Xa and anti-thrombin specific catalytic activities of UF and LMW heparins
Heparin type ATIII-binding capacity
(nmoVmg)
Catalytic activity
a-Xa
,  ,  - 1  ,  ,  1 .  l .(mln -  (Fg/mr)  - )
a-IIa
(mrn - (pg/mu ')
a-Xa
a-IIa
UF standard heparin
LMW standard heparin
CY216
Enoxaparin
cv222
29
43
48
29
47
9.8  +  0 .4
2 .8  +  0 .2
1 . 5  +  0 . 1
1 .4  +  0 .05
0.44 + 0.02
21.2  +  1 , .8
8 7  + 0 . 4
3 . 6  +  0 . 1
2 .8  +  0 .1
0.45 + 0 01
0 4 6
0.32
0.42
0.50
0.98
Human factor Xa or thrombin (30 nM) was added to 400 nM human ATIII and increasing concentrations of (LMW) heparin. Pseudo-first order rate
constants were determined from the initrai enzyme concentrations and the residual factor Xa (after 2 min reaction) and thrombin (after 30 s reaction)
concentrations. The rate constants were plotted vs. the heparin concentrations (cf. Fig.1). The increase of the rate constants per weight concentration
heparin were estimated by linear regression analysis, to reveal the anti-factor Xa (a-Xa) and anti-thrornbin (a-IIa) specific catalytic activities. Errors
represent the SE values of the estimates.
Table 3 Anli-factor Xa and anti-thrombin specific catalytic activities of subfractions of CY216
Heparin type ATIII-binding capacity
(nmol/mg)
Catalytic activity
a-Xa
(mrn - (pg/ml) -)
a-IIa
(mrn  ' (pg /ml )  ' )
a-Xa
a-IIa
CY216
MMW fraction
LMW fraction
Ultra LMW fraction
48
68
49
20
1 .5  +  0 .1
3.9 + 0.2
1.0 + 0.03
0 . 3 + 0 0 5
3 .6  +  0 .1
2 0 3 + 0 . 4
0.03 + 0.01
0
0.42
0 . 1 9
33.3
Experimental details as in Thble 2.
We want to note here, that calculations on molar basis will not be
realistic because of the dispersity of the ATIII-binding species in a
certain fraction. However, a dramatic decrease of the ATIII-
binding molarities with the decrease of the mean molecular
weights of the fractions is evident. As a consequence of the
decreased ATIII-binding capacities both the anti-factor Xa and
anti-thrombin catalytic activities of the fractions will decrease
with decreasing molecular weights. The more dramatic reduction
of the anti-thrombin catalytic activity is the result of an abolished
interaction between thrombin and heparin, due to the decreasing
heparin chain lengths. As a result, the anti-factor Xa over anti-
thrombin ratios of the fractions increase with decreasing mean
molecular weights.
So far the data have clearly demonstrated a marked dispersity
within a typical LMW heparin with respect to heparin species with
400 600
HEPARIN (ng/mt)
Fig. j PF4-binding equivalents of UF and LMW standard heparin. Anti-
factor Xa (O) and antithrombin (A) activities of variable concentrations
of UF standard heparin, and antithrombin activities (!) of variable
concentrations of LMW standard heparin were titrated with PF4, as in
Fig.2. Intersections of the linear extrapolations are shown as function of
the heparin concentrations. Solid lines were obtained by linear regression
analysis
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different activities. The important question that remains to be
answered, is whether or not the anticoagulant characteristics of a
LMW heparin preparation are to be found in a particular sub-
fraction. Regarding the anti-thrombin activity of CY216 it is clear
that this activity is exclusively found in the fraction that contains
heparin chains with a molecular weight between 6,100 and 11,200
(CY2l6 MMW fraction, mean molecular weight 7,900). The anti-
factor Xa activity is present in all heparin fractions. However, on
weight basis, the MMW fraction has the highest specific activity.
The data thus suggest that the distribution of the anticoagulant
heparin molecules in the entire preparation could be shifted to the
region of the higher molecular weights of the overall molecular
weight distribution pattern. Because the relative proportions of
the higher and lower molecular weight components do not differ
significantly (10), we conclude that the aveta9e apparent molecu-
lar weight of the heparin species which contribute to the total
anticoagulant activity of CY2t6, is significantly higher than the
average apparent molecular weight (5,100) of the complete
CY2l6 preparation.
Neutralization of Anti-Factor Xa and Anti-Thrombin Activities
of UF and LMW Standard Heparin by Platelet Factor 4
Fixed concentrations of UF and LMW standard heparin were
titrated with PF4, and the extent of neutralization of the anti-
factor Xa and anti-thrombin activities were determined as out-
lined in "Materials and Methods". Typical neutralization curves
are shown in Fig.2. As expected for UF heparin (Fig.2A), both
the anti-factor Xa and anti-thrombin activities were readily neu-
tralized. The sharpness of the inflection points of the neutraliza-
tion curves suggest a high affinity interaction between PF4 and the
heparin molecules with these anti-protease activities. Because of
this sharp transition, the inflection points, obtained from neutrali-
zation experiments at varying heparin concentrations, were taken
as measure for the PF4-binding normality of UF standard
heparin. A replot of these values against the heparin concentra-
tions is depicted in Fig.3. From the slope, estimated by linear
20
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regression analysis, it follows that the anti-factor Xa and anti-
thrombin activities of 1 mg of UF standard heparin are abolished
by 91 + 2 nmol PF4. From stoichiomctric titrations of ATIII (see
"Materials and Methods"), it followed that 1 mg of UF standard
heparin was equivalent to 29 nmol of ATIII-binding material.
That a 3-times higher PF4-binding normality was found than
could be expected on basis of the molar concentration of ATIII-
binding heparin species can be readily explained. Although only
about one-third of UF heparin binds to A-|III (24,25), still UF
standard heparin is largely (>95%) composed of heparin molecu-
les containing 18 saccharide residues or more, therefore each
heparin molecule can bind with high affinity to pF4, irrespective
of whether it contains the ATIII-binding pentasaccharide region
or not (15).
Typical curves of the neutralization of the anti-thrombin and
anti-factor Xa activities of the LMW standard heparin are shown
in Fig. 28. It is seen, that both the anti-thrombin and anti-
factor Xa activities can be completely abolished, although the
neutralization of anti-factor Xa activity requires somewhat higher
amounts of PF4.
The intersections of the linear extrapolations of the anti-
thrombin neutralization curves, obtained at varying heparin
concentrations, were replotted against the LMW standard hepa-
rin concentrations (Fig.3). From the slope, estimated by linear
regression analysis, it follows that the anti-thrombin activity of
1 mg of LMW standard heparin is abolished by an equivalent
amount of 43 + 1 nmol PF4. On basis of a mean molecular weisht
of 6,400 (Table 1), 1 mg of LMW standard heparin is estimated to
correspond to about 160 nmol of material. Thus, in contrast with
UF standard heparin, only a small fraction of LMW standard
heparin (approximately 25 mol%) has a high affinity for pF4. The
molar concentration of the ATIII-binding species, as determined
by the intrinsic fluorescence enhancement (see "Materials and
Methods"), was 43 nmol per mg LMW standard heparin. Evi-
dently, part of the ATIII-binding saccharides have a lower affinity
for PF4, which is (also) demonstrated by the more hyperbolic
naiure of the neutralization curves of the anti-factor Xa activities
( F i g . 2 B ) .
Neutralization of Anti-Factor Xa and Anti-Thrombin Activities
of CY216, Enoxaparin, and CY222
Fixed amounts of CY216, enoxaparin, and Cy222 were
titrated with PF4. Neutralization of the anti-protease activities is
shown in Fig.4 as function of PF4 concentrations. The heparin
concentrations employed corresponded to 100 nM, as calculated
from the weight amounts and the mean molecular weights
depicted in Table L. It is seen that the anti-thrombin activity of
each LMW heparin is completely, and with high affinity, abro-
gated by low amounts of PF4. On basis of the intersections of the
linear extrapolations, and utilizing their mean molecular weights,
it can be calculated fhat CY2'1,6, enoxaparin, and CY222 contain
about 10 mol%", 7 molY", and 5 mol% material, respectively,
which binds to PF4 with high affinity.
Neutralization of the anti-factor Xa activities of Cy216, enox-
aparin and CY222 follows a more complex pattern. The first 50%
of the activities are readily neutralized and seem to behave the
same as the neutralization of the anti-thrombin activities. How-
ever, maximum neutralization of the anti-factor Xa activities
requires more PF4 as compared to the complete neutralization of
the anti-thrombin activities, due to a pronounced hyperbolic
nature of the neutralization curves of anti-factor Xa activities. In
contrast with the LMW standard heparin, the anti-factor Xa
activities of CY21,6, enoxaparin and CY222 are not completely
abolished. From these neutralization curves (Figs.48, D, and F),
it is determined that about 5%, I\Y". and i,5% of the anti-
100
E
PLATELET FACTOR a (nM)
Flg.4 Neutralization of anti-thrombin and anti-factor Xa activities of
LMW heparin preparations by PF4. The anti-thrombin (panels A, C, and
E) and anti-factor Xa (panels B, D, and F) activities were neutralized by
increasing amounts of PF4, and expressed relative to the activities as
determined in the absence of PF4. The initial heparin concentrations were
510 ngCY2l6lml (A and B), 380 ng enoxaparin/ml (C and D), and 380 ng
CY222/ml (E and F)
factor Xa activities of CY2l6, enoxaparin, and CY222, respect-
ively, cannot be neutralized by a large molar excess of PF4. This
differential effect of increasing amounts of PF4 on the neutraliza-
tion curves can be explained by increasing amounts of saccharides
with anti-factor Xa and no anti-thrombin activities (M, <5,400),
which have a lower affinity for PF4, as compared to that of the
saccharides with both anti-factor Xa and anti-thrombin activities.
We also investigated the extent to which the anti-factor Xa
activities of the MMW LMW, and ultra LMW fractions of Cy2l6
could be neutralized by PF4. The relative amounts of the anti-
factor Xa activities which could be neutralized were 100"/", 407",
and 0Y", respectively. This clearly demonstrates that as the
heparin size goes from octadecasaccharide downwards, increasing
amounts of anti-factor Xa activity resist neutralization by PF4.
Discussion
It is generally accepted that ATIII-high affinity heparin
oligosaccharides with molecular weights less than 5,400
(octadecasaccharide) have negligible anti-thrombin activities,
while their potency to accelerate the inactivation of factor Xa is
preserved (3, 4). The work of Lane et al. (3) has also indicated
that the anti-thrombin and anti-factor Xa activities of these
heparin molecules are less amenable to neutralization by pF4. We
reasoned that regarding LMW heparin preparations mean
molecular weights as such might have no predictive value for their
anti-protease activities and their neutralization by pF4, because
these preparations encompass heparin chains in a wide range of
molecular weights with unknown distributions of the ATIII high
affinity molecules over the range of molecular weights. There-
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fore, we investigated in the present study whether or not LMW
heparin preparations like the 1st International Standard for LMW
heparin, CY2I6, enoxaparin, and Cy222 with mean molecular
weights of 6,400, 5,100, 3,800 and 3,800, respectively, have
identical properties with respect to factor Xa and thrombin
inactivation, and neutralization by pF4. We determined anti_
factor Xa and anti-thrombin specific catalytic activities, i.e. rate
constants normalized for the heparin concentrations, and evalu_
ated the PF4-dependent neutralization ofthese activities. Because
free calcium ions affect the rates of heparin-dependent inhibition
of factor Xa and thrombin by ATIII (Fig. 1), 4.0 mM CaCl2 was
inc luded in  a l l  our  exper iments .
We found that in a buffer system using purified proteases and
ATIII of human origin the ratios of anti-factor Xa activity over
anti-thrombin activity did not vary with average apparent molecu_
lar weights of the heparin preparations (Table 2). Even the ultra
LMW heparin CY222, which is prepared by exhaustive nitrous
acid depolymeization of pig mucosal heparin and has the highest
number of molecules wilh M, <2,500, had only a 2-fold higher
ratio than the other heparin preparations. The invariability ofthe
specific activity ratios is caused by a parallel decrease of the anti_
thrombin and anti-factor Xa activities with decreasins mean
molecular weights.
Because catalysis of the inactivation of thrombin requires a
heparin chain length of at least octadecasaccharide, it is obvious
that a decrease of the number of molecules wtth M, <5,400 leads
to a decrease of the anti-thrombin activity. At present two
phenomena can be thought responsible for the decrease of the
anti-factor Xa activity. First of all, we (12) and others (26) have
shown that when the heparin molecular weights decrease from
about 15,000 to I,71,4 (pentasaccharide) the rate constants of
inhibition of human factor Xa by human ATIII in the presence of
CaCl2 decrease. Secondly, and this in fact will contribute to the
former effect, the Ca2+-dependent enhancement of anti-factor Xa
activity decreases as the heparin molecular weight decreases from
12,000 downwards (11). Consequently, it is well possible, that an
increase of the number of heparin molecules with only anti_
factor Xa activity (M, <5,400) is counterbalanced by a lesser
enhancement of the inactivation reaction with factor Xa.
MMW and LMW fractions. The MMW fraction (6,100 <M,
<11,200) has a relatively low anti-factor Xa activity as compared
to its anti-thrombin activity (Table 3). The LMW fraction 6,EOO
<M, <5,500) which contributes for not more than 0.5% to the
anti-thrombin activity of CY2I6 has considerable anti-factor Xa
activity. Thus, admixture of the LMW fraction will restore the
reduced anti-factor Xa specific activity of the MMW fraction,
resulting in an unaltered specific anti-factor Xalanti_thrombin
ratio of CY2I6.
Thus, LMW heparin preparations are functionally equivalent
to UF standard heparin on basis of their specific activity ratios.
How does this compare with their sensitivity towards neutraliza_
tion by PF4? First of all, we found that the anti-thrombin and anti_
factor Xa activities of UF standard heparin were neutralized bv
stoichiometrical amounts of pF4. Neurral izat ion of the anti_
thrombin activities of the LMW heparin preparations followed
the same pattern as obtained with UF standard heparin. From
titrat ions with PF4 (Fig.2B, and Figs.4A, C, and E; i t  was
estimated, that LMW standard heparin, Cy2I6, enoxaparin, and
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CY222, contain on molar basis about 25%, l0%, 7%, and. 5y"
material, respectively, which binds to PF4 with high affinity.
Titrations of the anti-factor Xa catalytic activities of the LMW
heparin preparations with PF4 follow more complex patterns,
especially those of CY2I6, enoxaparin, and. Cy222. At least 50%
of their anti-factor Xa activities are readily neutralized by pF4.
Thus, these heparin molecules represent the fraction of the
heparin preparations with both anti-factor Xa and anti-thrombin
activity (M, >5,400). Another 50%, 45% , 40yo , and 35'/", of the
anti-factor Xa activities of LMW standard heparin, Cy2l6,
enoxaparin, and, CY222, respectively, are neutralized by relative
higher amounts of PF4. Hence, these heparin molecules, which
have no anti-thrombin activity (M, <5,400), have a lower affinity
for PF4. The remaining anti-factor Xa activities, varying between
5 to 15% of CY2l6, enoxaparin, and Cy222, could not be
neutralized by PF4 even at high PF4lheparin ratios.
In conclusion, LMW heparin preparations are as sensitive as
UF heparin regarding neutralization of their anti-thrombin
activities. However, whereas the anti-factor Xa activity of UF
heparin is equally well neutralized as its anti-thrombin activity,
PF4-dependent neutralization of the anti-factor Xa activities of
LMW heparin preparations suggests three pools of anti-factor Xa
activity. The first pool of activity is, just as the anti-thrombin
activities, readily neutralized by PF4, the second one is neu-
tralized by excess PF4, and the remaining activities are rather
insensitive to PF4. Therefore, PF4 dependent neutralization of
the anti-factor Xa activity of a particular LMW heparin prepara-
tion will strongly depend on the heparin molecular weight
distribution pattern and on the local PF4 and heparin concentra-
tions.
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Tirt loot presents new aspects of surgical river anatomy, haemostasis,
management of hepatic traumata, surgical techniques in benign and malig-
nant liver tumours and surgical strategy incases ofbile duct atresias. In the
final chapter the authors critically discuss the perspectives of liver trans-
plantation. In favour of a functional view and in a practicerelated manner,
the usual schematic systematization was intentionally dispensed with. The
authors often deal with controversiai problems reporting different perspec-
tives and experiences. However, they succeeded in achieving ineach chap-
ter a sound consensus.
Thus, it was managed toplace liver surgery in the child synoptrcally on a
rational foundation. Since, up to now, such summary is lacking in intema-
tional literature, a group of intemational authors were able t0 fill a gap in
scientific literature.
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